IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

Sponsor

National Cancer Institute (NCI) (NIH)

Overall Status

Completed

CT.gov ID

NCT00609141

Collaborator

(none)

Enrollment

Location

Arm

Study Details

Study Description

Brief Summary

This phase I clinical trial is studying the side effects and best dose of IMC-A12 in treating young patients with relapsed or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumors. Monoclonal antibodies, such as IMC-A12, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Unspecified Childhood Solid Tumor, Protocol Specific	Biological: cixutumumab Other: pharmacological study Other: laboratory biomarker analysis	Phase 1

Detailed Description

PRIMARY OBJECTIVES:

To estimate the maximum tolerated dose (MTD) or recommended phase II dose of IMC-A12 (cixutumumab) in children with relapsed or refractory solid tumors using a limited dose-escalation strategy.
To define and describe the toxicities of this drug in children with relapsed or refractory solid tumors.
To characterize the pharmacokinetics of this drug in children with relapsed or refractory solid tumors.

SECONDARY OBJECTIVES:

To preliminarily define the antitumor activity of this drug in children with relapsed or refractory solid tumors within the confines of a phase I study.
To obtain initial phase II efficacy data on the antitumor activity of this drug in children with Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET).
To examine change in IGF-IR and insulin receptor (IR) levels and IGF-IR and IR activation in lymphocytes as biomarkers of IMC-A12 action and specificity.
To evaluate the effect of this drug on circulating levels of proteins involved in linear growth and glucose homeostasis, including IGF-I, IGF-II, IGF-BP3, growth hormone, insulin, and C-peptide.
To develop exploratory data concerning biomarkers of activity.

OUTLINE: This is a dose-escalation study.

Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.

Patients undergo blood sample collection periodically for pharmacokinetic, immunogenicity, and other correlative studies. Samples are analyzed for serum levels of IGF-I, IGF-II, IGF-BP3, growth hormone, insulin, and C-peptide; trough concentrations and PK sampling; and biomarkers, including IGF-IR expression and phosphorylation and insulin receptor expression and phosphorylation via immunoprecipitation and Western immunoblotting. Tumor tissue samples from patients with Ewing sarcoma/peripheral PNET are banked for future research.

After completion of study treatment, patients are followed at 30 days.

Study Design

Study Type:

Interventional

Actual Enrollment :

34 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors

Study Start Date :

Jan 1, 2008

Actual Primary Completion Date :

Sep 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (monoclonal antibody therapy) Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.	Biological: cixutumumab Given IV Other Names: anti-IGF-1R recombinant monoclonal antibody IMC-A12 IMC-A12 Other: pharmacological study Correlative studies Other Names: pharmacological studies Other: laboratory biomarker analysis Correlative studies

Arm

Intervention/Treatment

Experimental: Treatment (monoclonal antibody therapy)

Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.

Biological: cixutumumab

Given IV

Other Names:

anti-IGF-1R recombinant monoclonal antibody IMC-A12

IMC-A12

Other: pharmacological study

Correlative studies

Other Names:

pharmacological studies

Other: laboratory biomarker analysis

Correlative studies

Outcome Measures

Primary Outcome Measures

Adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 [Weekly during each course]
Toxicity tables will be constructed to summarize the observed incidence by severity and type of toxicity.
MTD or recommended phase II dose [During course 1]
MTD will be the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT). DLT is defined as any hematological and non-hematological toxicities that is possible, probably, or definitely attributed to IMC-A12.
Pharmacokinetics of IMC-A12 [At baseline, days 1, 8, 15, 22, and 28 of course 1, and days 15 and 28 of course 2]

Secondary Outcome Measures

Response rate (complete or partial response) in patients with Ewing sarcoma/peripheral PNET [Up to 30 days after completion of treatment]
Confidence intervals will be constructed according to the method of Chang and O'Brien to account for the two-stage design.

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Year to 21 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically confirmed solid tumor
Relapsed or refractory disease
No central nervous system (CNS) tumor or lymphoma
Histological confirmation may have been made at original diagnosis or at relapse
Current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
Measurable or evaluable disease
Patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET) must have tissue blocks or slides available
Study chair must be notified if tissue blocks or slides are not available
Karnofsky performance status (PS) ≥ 50% (patients > 10 years of age) and Lansky (PS) ≥ 50% (patients ≤ 10 years of age)
Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age/gender as follows:
1 to < 2 years (males and females 0.6 mg/dL)
2 to < 6 years (males and females 0.8 mg/dL)
6 to < 10 years (males and females 1.0 mg/dL)
10 to < 13 years (males and females 1.2 mg/dL)
13 to < 16 years (males 1.5 mg/dL and females 1.4 mg/dL)
≥ 16 years (males 1.7 mg/dL and females 1.4 mg/dL)
Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
SGPT (ALT) ≤ 110 μ/L (for the purpose of this study, the ULN for SGPT is 45 μ/L)
Serum albumin ≥ 2 g/dL
Patients with known bone marrow metastatic disease will be eligible for study but not evaluable for hematologic toxicity
Patients must not be known to be refractory to red cell or platelet transfusion
Patients with solid tumors without bone marrow involvement must meet the following criteria:
Peripheral absolute neutrophil count ≥ 1,000/μL
Platelet count ≥ 100,000/μL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after completion of study therapy
No uncontrolled infection
No known type I or type II diabetes mellitus
Able to comply with the safety monitoring requirements of the study, in the opinion of the investigator
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to IMC-A12
Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
At least 7 days since prior and no concurrent hematopoietic growth factors
Growth factors that support platelet or white cell number or function can only be administered for culture-proven bacteremia or invasive fungal infection
At least 7 days since prior and no concurrent biologic antineoplastic agents
At least 6 weeks since prior monoclonal antibodies
At least 3 months since prior total body irradiation (TBI), craniospinal external radiotherapy (XRT), or ≥ 50% radiotherapy to the pelvis
At least 2 weeks since prior local XRT (small port)
At least 6 weeks since other prior substantial bone marrow radiotherapy
More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)
More than 7 days since prior and no concurrent systemic corticosteroids
Prior stem cell transplant or rescue allowed provided there has been no evidence of active graft-versus-host-disease within the past 2 months
No prior monoclonal antibody therapy targeting the IGF-IR
No concurrent chemotherapy, radiotherapy, or immunotherapy
No concurrent anticancer agents
No concurrent insulin or growth hormone therapy
No other concurrent investigational drugs